Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2022 Results
Surgalign Holdings, Inc. (NASDAQ: SRGA) reported Q4 and full-year 2022 results, highlighting a revenue decline to $20.6 million from $21.8 million year-over-year. GAAP gross margin was -13.6%, down from 56.5% in Q4 2021 due to inventory write-downs related to restructuring. Nonetheless, total operating expenses decreased significantly to $45.3 million from $105 million a year prior. The company successfully closed a $12 million offering and sold its Coflex product line for $17 million, boosting its cash position. Surgalign aims to achieve $30-$35 million in cash savings in 2023 and believes it can maintain liquidity through Q4 2023.
- Closed $12 million Registered Direct Offering, adding $10.8 million cash.
- Sold Coflex product line, enhancing liquidity by $14.8 million.
- Targeting $30-$35 million in cash savings for 2023.
- Q4 revenue decreased to $20.6 million from $21.8 million YOY.
- GAAP gross margin fell to -13.6%, down from 56.5% YOY.
- Operating loss of $48.2 million compared to $92.6 million YOY.
DEERFIELD, Ill., March 30, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for its fourth quarter and full year 2022 ending December 31, 2022.
2022 Fourth Quarter and Subsequent 2023 Corporate Highlights:
- Expansion of HOLO Portal™ into Virginia and Texas; over 30 cases performed since commercial launch
- Launched HOLO™ AI Insights, part of the HOLO AI portfolio, to provide powerful population analytics of spine MRI images
- HOLO Portal receives 2022 Best New Technology Award from Orthopedics This Week
- 100th case completed utilizing the Cortera™ Spinal Fixation System
- Closed
$12.0 million Registered Direct Offering in Q4 providing net cash of$10.8 million to balance sheet - Sold its Coflex® and CoFix product line to Xtant Medical Holdings, Inc. on February 28, 2023 for
$17.0 million , adding net cash of$14.8 million to balance sheet - Company continues to execute its corporate restructuring program; on track to realize targeted cash savings of
$30 t o$35 million in 2023 (compared to 2022)
"I'm very proud of the team as we continue to transform our business and realign both products and resources, working productively with our customers throughout," stated Terry Rich, President and Chief Executive Officer. “We are focused on becoming a leader in Digital Health, through both commercialization of new products and ongoing technology innovation. During the first quarter, we enhanced our HOLO Portal surgical guidance system and launched HOLO AI Insights, broadening our future offering and market potential. We believe our AI platform is leading the market and has the potential to drive better patient outcomes."
Financial Update
Total revenue for the three months ended December 31, 2022, was
A large write-down of inventory related to product rationalization undertaken by the Company as part of its corporate restructuring, which began in the fourth quarter of 2022, led to GAAP gross margin of -
On a non-GAAP basis, the Company reported adjusted gross margin of
Total GAAP operating expenses for the three months ended December 31, 2022 were
On a non-GAAP basis, total adjusted operating expenses for the three months ended December 31, 2022 were
The Company reported an operating loss of
Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) for the three months ended December 31, 2022 was a loss of
As of December 31, 2022, cash and cash equivalents were approximately
The Company continues to implement a corporate-wide review of its organizational structure, processes and costs, along with continued product rationalization initiatives. As announced on March 6, 2023, the Company remains on track to achieve its target cash savings of
Conference Call
Surgalign will host a conference call and audio webcast at 4:30 p.m. ET today. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or (201) 689-8043 (International). The webcast can be accessed through the investor section of Surgalign’s website at surgalign.com/investors/. A replay of the conference call will be available on Surgalign’s website for one month following the call.
About Surgalign Holdings, Inc.
Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies physicians and other health providers will look to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets products throughout the United States and in approximately 40 countries worldwide through its network of top independent distributors. Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management, and such forward-looking statements include (among others) statements regarding anticipated future financial and operating performance (including forecasted full-year revenue and number of HOLO sites secured), product rationalization and expense reduction initiatives and the results thereof, potential third party financing and anticipated cash needs. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company’s industry, and numerous other factors and risks identified in the Company’s most recent Form 10-K, 10-Q and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the Company’s access to adequate operating cash flow, trade credit, borrowed funds and equity capital to fund its operations and pay its obligations as they become due, and the terms on which external financing may be available, including the impact of adverse trends or disruption in the global credit and equity markets; (ii) risks relating to existing or potential litigation or regulatory actions; (iii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting; (iv) general worldwide economic conditions and related uncertainties; (v) the continued impact of the COVID-19 and the Company’s attempts at mitigation, particularly in international markets served by the Company; (vi) the failure by the Company to identify, develop and successfully implement its strategic initiatives, particularly with respect to its digital surgery strategy ; (vii) the reliability of our supply chain; (viii) our ability to meet obligations, including purchase minimums, under our vendor and other agreements; (ix) whether or when the demand for procedures involving our products will increase; (x) our financial position and results, total revenue, product revenue, gross margin, and operations; (xi) failure to realize, or unexpected costs in seeking to realize, the expected benefits of the Holo Surgical Inc. (“Holo Surgical”) and Inteneural Networks Inc. (“INN”) acquisitions, including the failure of Holo Surgical’s and INN’s products and services to be satisfactorily developed or achieve applicable regulatory approvals or as a result of the failure to commercialize and distribute its products; (xii) the failure to effectively integrate Holo Surgical’s and INN’s operations with those of the Company, including: retention of key personnel; the effect on relationships with customers, suppliers, and other third parties; and the diversion of management time and attention to the integration; (xiii) the number of shares and amount of cash that will be required in connection with any post-closing milestone payments, including as a result of changes in the trading price of the Company’s common stock and their effect on the amount of cash needed by the Company to fund any post-closing milestone payments in connection with the acquisitions; (xiv) the continuation of recent quality issues with respect to our global supply chain (xv) the effect and timing of changes in laws or in governmental regulations; and (xvi) other risks described in our public filings with the SEC. These factors should be considered carefully, and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company's SEC filings may be obtained by contacting the Company or the SEC or by visiting Surgalign's website at http://www.surgalign.com/ or the SEC’s website at http://www.sec.gov/. We undertake no obligation to update these forward-looking statements except as may be required by law.
Investor and Media Relations Contact:
Glenn Wiener
GW Communications
T: +1 (917) 887 8434
E: gwiener@gwcco.com
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited, in thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended | For the Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | $ | 20,573 | $ | 21,830 | $ | 81,979 | $ | 90,500 | ||||||||
| Costs of goods sold | 23,381 | 9,497 | 41,691 | 29,775 | ||||||||||||
| Gross profit | (2,808 | ) | 12,333 | 40,288 | 60,725 | |||||||||||
| Operating Expenses: | ||||||||||||||||
| General and administrative | 22,427 | 25,414 | 95,888 | 104,460 | ||||||||||||
| Severance and restructuring costs | 1,148 | (10 | ) | 1,148 | 208 | |||||||||||
| Research and development | 3,334 | 4,928 | 15,736 | 13,888 | ||||||||||||
| Gain on acquisition contingency | (683 | ) | (1,034 | ) | (17,867 | ) | (4,587 | ) | ||||||||
| Asset acquisition expenses | — | 72,087 | — | 72,087 | ||||||||||||
| Asset impairment and abandonments | 1,082 | 2,401 | 5,352 | 12,195 | ||||||||||||
| Transaction and financing expenses | 18,039 | 1,179 | 19,391 | 3,689 | ||||||||||||
| Total operating expenses | 45,347 | 104,965 | 119,648 | 201,940 | ||||||||||||
| Other operating income, net | — | — | (898 | ) | (3,932 | ) | ||||||||||
| Operating loss | (48,155 | ) | (92,632 | ) | (78,462 | ) | (137,283 | ) | ||||||||
| Other expense (income) - net | ||||||||||||||||
| Other expense (income) - net | (353 | ) | 19 | 26 | (202 | ) | ||||||||||
| Interest expense | 253 | — | 1,009 | — | ||||||||||||
| Foreign exchange (gain) loss | (1,699 | ) | 526 | 978 | 1,447 | |||||||||||
| Change in fair value of warrant liability | (5,910 | ) | (4,474 | ) | (24,827 | ) | (14,736 | ) | ||||||||
| Total other income - net | (7,709 | ) | (3,929 | ) | (22,814 | ) | (13,491 | ) | ||||||||
| Loss before income tax provision | (40,446 | ) | (88,703 | ) | (55,648 | ) | (123,792 | ) | ||||||||
| Income tax (benefit) provision | (1,335 | ) | 118 | (1,043 | ) | (886 | ) | |||||||||
| Net loss from continuing operations | (39,111 | ) | (88,821 | ) | (54,605 | ) | (122,906 | ) | ||||||||
| Discontinued operations (Note 5) | ||||||||||||||||
| Loss from operations of discontinued operations | — | — | — | (6,316 | ) | |||||||||||
| Income tax benefit | — | (1,562 | ) | — | (2,674 | ) | ||||||||||
| Net loss from discontinued operations | — | 1,562 | — | (3,642 | ) | |||||||||||
| Net loss | (39,111 | ) | (87,259 | ) | (54,605 | ) | (126,548 | ) | ||||||||
| Net loss applicable to noncontrolling interests | — | 41,897 | — | 41,897 | ||||||||||||
| Net loss applicable to Surgalign Holdings, Inc. | $ | (39,111 | ) | $ | (45,362 | ) | $ | (54,605 | ) | $ | (84,651 | ) | ||||
| Net loss from continuing operations per share applicable to Surgalign Holdings, Inc. - basic | $ | (5.77 | ) | $ | (19.23 | ) | $ | (8.33 | ) | $ | (30.08 | ) | ||||
| Net loss from continuing operations per share applicable to Surgalign Holdings, Inc. - diluted | $ | (5.77 | ) | $ | (19.23 | ) | $ | (8.33 | ) | $ | (30.08 | ) | ||||
| Net gain (loss) from discontinued operations per share applicable to Surgalign Holdings, Inc. - basic | $ | — | $ | 0.34 | $ | — | $ | (0.89 | ) | |||||||
| Net gain (loss) from discontinued operations per share applicable to Surgalign Holdings, Inc. - diluted | $ | — | $ | 0.34 | $ | — | $ | (0.89 | ) | |||||||
| Net loss per share applicable to Surgalign Holdings, Inc. - basic | $ | (5.77 | ) | $ | (9.82 | ) | $ | (8.33 | ) | $ | (20.72 | ) | ||||
| Net loss per share applicable to Surgalign Holdings, Inc. - diluted | $ | (5.77 | ) | $ | (9.82 | ) | $ | (8.33 | ) | $ | (20.72 | ) | ||||
| Weighted average shares outstanding - basic | 6,780,777 | 4,617,806 | 6,555,207 | 4,086,409 | ||||||||||||
| Weighted average shares outstanding - diluted | 6,780,777 | 4,617,806 | 6,555,207 | 4,086,409 | ||||||||||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited, in thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Cash | $ | 16,295 | $ | 51,287 | ||||
| Accounts receivable - net | 16,057 | 19,197 | ||||||
| Current inventories - net | 17,710 | 26,204 | ||||||
| Prepaid and other assets | 6,649 | 9,984 | ||||||
| Total current assets | $ | 56,711 | $ | 106,672 | ||||
| Non-current inventories - net | 5,947 | 10,212 | ||||||
| Property, plant and equipment - net | 2,057 | 945 | ||||||
| Other assets - net | 5,527 | 5,970 | ||||||
| Total assets | $ | 70,242 | $ | 123,799 | ||||
| Liabilities, Mezzanine Equity and Stockholders' Equity | ||||||||
| Accounts payable | $ | 7,705 | $ | 10,204 | ||||
| Current portion of acquisition contingency - Holo | — | 25,585 | ||||||
| Accrued expenses and other current liabilities | 13,146 | 17,769 | ||||||
| Accrued income taxes | 296 | 484 | ||||||
| Total current liabilities | $ | 21,147 | $ | 54,042 | ||||
| Notes payable - related party | 10,192 | 9,982 | ||||||
| Acquisition contingencies - Holo | 24,061 | 26,343 | ||||||
| Warrant liability | 22,982 | 12,013 | ||||||
| Other Long-term liabilities | 7,583 | 3,176 | ||||||
| Total liabilities | $ | 85,965 | $ | 105,556 | ||||
| Mezzanine equity | 10,006 | 10,006 | ||||||
| Stockholders' equity: | ||||||||
| Common stock and additional paid-in capital | 601,329 | 579,670 | ||||||
| Accumulated other comprehensive loss | (2,840 | ) | (1,820 | ) | ||||
| Accumulated deficit | (624,218 | ) | (569,613 | ) | ||||
| Total stockholders' equity | $ | (25,729 | ) | $ | 8,237 | |||
| Total liabilities and stockholders' equity | $ | 70,242 | $ | 123,799 | ||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited, in thousands) | ||||||||
| For the Twelve Months Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (54,605 | ) | $ | (126,548 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | 2,183 | 2,479 | ||||||
| Provision for bad debts and product returns | 1,895 | 2,064 | ||||||
| Change in fair value of warrant liability | (24,827 | ) | (14,736 | ) | ||||
| Provision for inventory write-downs | 19,972 | 9,096 | ||||||
| Investor fee for warrant financing | 916 | 2,119 | ||||||
| Financing fee for warrant financing | 17,042 | — | ||||||
| Deferred income tax provision | (1,251 | ) | (171 | ) | ||||
| Stock-based compensation | 4,634 | 5,212 | ||||||
| Asset impairment and abandonments | 5,352 | 12,195 | ||||||
| Asset acquisition expenses | — | 72,087 | ||||||
| Gain on acquisition contingency | (17,867 | ) | (4,587 | ) | ||||
| Bargain purchase gain | — | (90 | ) | |||||
| Loss on sale of OEM business (discontinued operations) | — | 6,316 | ||||||
| Other | (3 | ) | 24 | |||||
| Change in assets and liabilities: | ||||||||
| Accounts receivable | 1,182 | 5,701 | ||||||
| Inventories | (7,858 | ) | (15,480 | ) | ||||
| Accounts payable | (2,442 | ) | (3,112 | ) | ||||
| Accrued expenses and income taxes payable | (20,317 | ) | 10,542 | |||||
| Right-of-use asset and lease liability | (174 | ) | (2,542 | ) | ||||
| Other operating assets and liabilities | 24,059 | (12,361 | ) | |||||
| Net cash used in operating activities | $ | (52,109 | ) | $ | (51,792 | ) | ||
| Cash flows from investing activities: | ||||||||
| Payments for OEM working capital adjustment | — | (5,430 | ) | |||||
| Purchases of property and equipment | (6,781 | ) | (13,423 | ) | ||||
| Patent and acquired intangible asset costs | (475 | ) | (649 | ) | ||||
| Acquisition of INN | — | (5,000 | ) | |||||
| Business acquisitions, net of cash acquired | — | (330 | ) | |||||
| Net cash used in investing activities | $ | (7,256 | ) | $ | (24,832 | ) | ||
| Cash flows from financing activities: | ||||||||
| Share offering proceeds, net | 28,563 | 82,326 | ||||||
| Pre-funded warrant execution | 1 | — | ||||||
| Proceeds from exercise of common stock options | — | 23 | ||||||
| Proceeds from Employee Stock Purchase Program (ESPP) | 246 | 407 | ||||||
| Repayment of Holo milestones | (4,081 | ) | — | |||||
| Payments for treasury stock | (71 | ) | (196 | ) | ||||
| Net cash provided by financing activities | $ | 24,658 | $ | 82,560 | ||||
| Effect of exchange rate changes on cash and cash equivalents | (285 | ) | 1,389 | |||||
| Net increase (decrease) in cash and cash equivalents | (34,992 | ) | 7,325 | |||||
| Cash and cash equivalents, beginning of period | 51,287 | 43,962 | ||||||
| Cash and cash equivalents, end of period | $ | 16,295 | $ | 51,287 | ||||
Non-GAAP Financial Measures
To supplement our consolidated financial statements presented on a GAAP basis, we disclose non-GAAP net loss applicable to common shares, non-GAAP net loss per diluted share, non-GAAP operating expenses, and non-GAAP gross profit, in each case adjusted for certain amounts. In addition, we disclose EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. The calculation of the tax effect on the adjustments between GAAP net loss applicable to common shares and non-GAAP net loss applicable to common shares is based upon our estimated annual GAAP tax rate, adjusted to account for items excluded from GAAP net loss applicable to common shares in calculating non-GAAP net loss applicable to common shares. Reconciliations of each of these non-GAAP financial measures to the most directly comparable GAAP measures are included in the reconciliations below.
The following are explanations of the adjustments that management excluded as part of the non-GAAP measures for the years ended December 31, 2022 and 2021. Management removes the amount of these costs including the tax effect on the adjustments from our operating results to supplement a comparison to our past operating performance.
2022 and 2021 Non-cash stock-based compensation – These costs relate to expense amortization for all stock-based awards made to employees and directors, including restricted stock awards, restricted stock units, stock options and the employee stock purchase plan purchase rights.
2022 and 2021 Foreign exchange loss – These costs relate to the process of remeasuring international activity into the Company's functional currency.
2022 and 2021 Change in fair value of warrant liability – Other income related to the revaluation of our warrant liability.
2022 and 2021 Gain on acquisition contingency – The gain on acquisition contingency relates to an adjustment to our estimate of obligation for future milestone payments on the Holo Surgical acquisition.
2022 and 2021 Asset impairment and abandonments – These costs relate to asset impairment and abandonments of certain long-term assets within the asset group.
2022 and 2021 Inventory purchase price adjustment – These costs relate to the purchase price effects of acquired Paradigm inventory that was sold during the years ended December 31, 2022 and 2021.
2022 and 2021 Transaction and financing expenses – These costs relate to professional fees associated with financings and issuance costs for the registered direct offering and professional fees associated with the acquisition of INN, Holo Surgical, and Prompt Prototypes, LLC.
2022 and 2021 Tax effect on other adjustments – These adjustments represent the tax effects of the non-GAAP measures for the respective years.
2022 and 2021 Severance and restructuring costs – 2022 costs relate to employee related severance costs as a result of the Company’s organization restructuring plan. 2021 costs relate to the reduction of our organizational structure, primarily driven by simplification of our Marquette, MI location.
2022 and 2021 Other operating income, net – Gain relates to the Company’s inventory settlement with OEM.
2022 Inventory write-off – These costs relate to inventory write-offs associated with reduced sales forecasts applied for the Company’s continuing inventory product portfolio.
2022 Product rationalization – These costs relate to inventory write downs associated with the Company’s product portfolio rationalization initiative and wind down of the international business.
2021 Bargain purchase gain – Gain related to our acquisition of Prompt Prototypes, LLC.
2021 Supplier prepayment write-off – Cost related to the write-off of prepaid royalty payments that the Company assessed would not be met in future years.
2021 Asset acquisition expenses – The asset acquisition expenses related to the INN acquisition in 2021.
Material Limitations Associated with the Use of Non-GAAP Financial Measures
EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares should not be considered in isolation, or as a replacement for GAAP measures.
Usefulness of Non-GAAP Financial Measures to Investors
The Company believes that presenting EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making.
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||||||||||
| Reconciliation of Revenues to Adjusted Gross Profit | ||||||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | $ | 20,573 | $ | 21,830 | $ | 81,979 | $ | 90,500 | ||||||||
| Costs of processing and distribution | 23,381 | 9,497 | 41,691 | 29,775 | ||||||||||||
| Gross profit, as reported | (2,808 | ) | 12,333 | 40,288 | 60,725 | |||||||||||
| Inventory write-off | 3,174 | — | 3,709 | — | ||||||||||||
| Product rationalization | 13,822 | — | 13,822 | — | ||||||||||||
| Supplier prepayment write-off | 180 | 3,000 | 180 | 3,000 | ||||||||||||
| Inventory purchase price adjustment | 423 | 497 | 1,678 | 2,036 | ||||||||||||
| Non-GAAP gross profit, adjusted | $ | 14,791 | $ | 15,830 | $ | 59,677 | $ | 65,761 | ||||||||
| Non-GAAP gross profit percentage, adjusted | 71.9 | % | 72.5 | % | 72.8 | % | 72.7 | % | ||||||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | |||||||||||||||
| Non-GAAP Operating Expenses, Adjusted | |||||||||||||||
| (Unaudited, in thousands) | |||||||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Operating Expenses | $ | 45,347 | $ | 104,965 | $ | 119,648 | $ | 201,940 | |||||||
| Non-cash stock-based compensation | 1,122 | 994 | 4,634 | 5,212 | |||||||||||
| Gain on acquisition contingency | (683 | ) | (1,034 | ) | (17,867 | ) | (4,587 | ) | |||||||
| Asset acquisition expenses | — | 72,087 | — | 72,087 | |||||||||||
| Bargain purchase gain | — | — | — | (90 | ) | ||||||||||
| Asset impairment and abandonments | 1,082 | 2,401 | 5,352 | 12,195 | |||||||||||
| Transaction and financing expenses | 18,039 | 1,179 | 19,391 | 3,689 | |||||||||||
| Severance and restructuring costs | 1,148 | (10 | ) | 1,148 | 208 | ||||||||||
| Non-GAAP operating expenses, adjusted* | $ | 24,639 | $ | 29,348 | $ | 106,990 | $ | 113,226 | |||||||
| Non-GAAP operating expenses, adjusted, as a percent of revenues | 119.8 | % | 134.4 | % | 130.5 | % | 125.1 | % | |||||||
| *Please note this reconciliation does not include HOLO Portal capitalized costs of | |||||||||||||||
| #See explanations in Non-GAAP Financial Measures above. | |||||||||||||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||||||||||
| Reconciliation of Net Loss Applicable to Common Shares and Net Loss Income Per Diluted Share to Adjusted Net Loss Applicable to Common Shares and Adjusted Net Loss Per Diluted Share | ||||||||||||||||
| (Unaudited, in thousands except per share data) | ||||||||||||||||
| For the Three Months Ended | ||||||||||||||||
| December 31, 2022 | December 31, 2021 | |||||||||||||||
| Net (Loss) Income Applicable to Common Shares | Amount Per Diluted Share | Net (Loss) Income Applicable to Common Shares | Amount Per Diluted Share | |||||||||||||
| Net loss from continuing operations, as reported | $ | (39,111 | ) | $ | (5.77 | ) | $ | (88,821 | ) | $ | (19.23 | ) | ||||
| Change in fair value of warrant liability | (5,910 | ) | (0.87 | ) | (4,474 | ) | (0.97 | ) | ||||||||
| Gain on acquisition contingency | (683 | ) | (0.10 | ) | (1,034 | ) | (0.22 | ) | ||||||||
| Non-cash stock-based compensation | 1,122 | 0.17 | 994 | 0.22 | ||||||||||||
| Foreign exchange (gain) loss | (1,699 | ) | (0.25 | ) | 526 | 0.11 | ||||||||||
| Supplier prepayment write-off | 180 | 0.03 | 3,000 | 0.65 | ||||||||||||
| Asset acquisition expenses | — | 0.00 | 72,087 | 15.61 | ||||||||||||
| Asset impairment and abandonments | 1,082 | 0.16 | 2,401 | 0.52 | ||||||||||||
| Transaction and financing expenses | 18,039 | 2.66 | 1,179 | 0.26 | ||||||||||||
| Inventory purchase price adjustment | 423 | 0.06 | 497 | 0.11 | ||||||||||||
| Inventory write-off | 3,174 | 0.47 | — | 0.00 | ||||||||||||
| Product rationalization | 13,822 | 2.04 | — | 0.00 | ||||||||||||
| Severance and restructuring costs | 1,148 | 0.17 | (10 | ) | 0.00 | |||||||||||
| Tax effect on other adjustments | 33 | 0.00 | — | 0.00 | ||||||||||||
| Non-GAAP net loss applicable to common shares, adjusted* | $ | (8,380 | ) | $ | (1.22 | ) | $ | (13,655 | ) | $ | (2.94 | ) | ||||
| *Please note this reconciliation does not include HOLO Portal capitalized costs of | ||||||||||||||||
| #See explanations in Non-GAAP Financial Measures above. | ||||||||||||||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||||||||||
| Reconciliation of Net Loss Applicable to Common Shares and Net Loss Income Per Diluted Share to Adjusted Net Loss Applicable to Common Shares and Adjusted Net Loss Per Diluted Share | ||||||||||||||||
| (Unaudited, in thousands except per share data) | ||||||||||||||||
| For the Twelve Months Ended | ||||||||||||||||
| December 31, 2022 | December 31, 2021 | |||||||||||||||
| Net (Loss) Income Applicable to Common Shares | Amount Per Diluted Share | Net (Loss) Income Applicable to Common Shares | Amount Per Diluted Share | |||||||||||||
| Net loss from continuing operations, as reported | $ | (54,605 | ) | $ | (8.33 | ) | $ | (122,906 | ) | $ | (30.08 | ) | ||||
| Change in fair value of warrant liability | (24,827 | ) | (3.79 | ) | (14,736 | ) | (3.61 | ) | ||||||||
| Gain on acquisition contingency | (17,867 | ) | (2.73 | ) | (4,587 | ) | (1.12 | ) | ||||||||
| Non-cash stock-based compensation | 4,634 | 0.71 | 5,212 | 1.28 | ||||||||||||
| Foreign exchange loss | 978 | 0.15 | 1,447 | 0.35 | ||||||||||||
| Supplier prepayment write-off | 180 | 0.03 | 3,000 | 0.73 | ||||||||||||
| Asset acquisition expenses | — | 0.00 | 72,087 | 17.64 | ||||||||||||
| Bargain purchase gain | — | 0.00 | (90 | ) | (0.02 | ) | ||||||||||
| Other operating income | (898 | ) | (0.14 | ) | (3,932 | ) | (0.96 | ) | ||||||||
| Asset impairment and abandonments | 5,352 | 0.82 | 12,195 | 2.98 | ||||||||||||
| Transaction and financing expenses | 19,391 | 2.96 | 3,689 | 0.90 | ||||||||||||
| Inventory purchase price adjustment | 1,678 | 0.26 | 2,036 | 0.50 | ||||||||||||
| Inventory write-off | 3,709 | 0.57 | — | 0.00 | ||||||||||||
| Product rationalization | 13,822 | 2.11 | — | 0.00 | ||||||||||||
| Severance and restructuring costs | 1,148 | 0.18 | 208 | 0.05 | ||||||||||||
| Tax effect on other adjustments | 33 | 0.01 | (28 | ) | (0.01 | ) | ||||||||||
| Non-GAAP net loss applicable to common shares, adjusted* | $ | (47,272 | ) | $ | (7.19 | ) | $ | (46,405 | ) | $ | (11.37 | ) | ||||
| *Please note this reconciliation does not include HOLO Portal capitalized costs of | ||||||||||||||||
| #See explanations in Non-GAAP Financial Measures above. | ||||||||||||||||
| SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES | ||||||||||||||||
| Reconciliation of Net Loss Applicable to Commons Shares to Adjusted EBITDA | ||||||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net loss income for continuing operations | $ | (39,111 | ) | $ | (88,821 | ) | $ | (54,605 | ) | $ | (122,906 | ) | ||||
| Interest expense, net | 253 | — | 1,009 | — | ||||||||||||
| (Benefit) provision for income taxes | (1,335 | ) | 118 | (1,043 | ) | (886 | ) | |||||||||
| Depreciation | 398 | 602 | 1,973 | 2,457 | ||||||||||||
| EBITDA | (39,795 | ) | (88,101 | ) | (52,666 | ) | (121,335 | ) | ||||||||
| Reconciling items impacting EBITDA | ||||||||||||||||
| Non-cash stock based compensation | 1,122 | 994 | 4,634 | 5,212 | ||||||||||||
| Foreign exchange (gain) loss | (1,699 | ) | 526 | 978 | 1,447 | |||||||||||
| Other reconciling items * | ||||||||||||||||
| Inventory write-off | 3,174 | — | 3,709 | — | ||||||||||||
| Supplier prepayment write-off | 180 | 3,000 | 180 | 3,000 | ||||||||||||
| Product rationalization | 13,822 | — | 13,822 | — | ||||||||||||
| Other operating income | — | — | (898 | ) | (3,932 | ) | ||||||||||
| Inventory purchase price adjustment | 423 | 497 | 1,678 | 2,036 | ||||||||||||
| Asset acquisition expenses | — | 72,087 | — | 72,087 | ||||||||||||
| Change in fair value of warrant liability | (5,910 | ) | (4,474 | ) | (24,827 | ) | (14,736 | ) | ||||||||
| Gain on acquisition contingency | (683 | ) | (1,034 | ) | (17,867 | ) | (4,587 | ) | ||||||||
| Bargain purchase gain | — | — | — | (90 | ) | |||||||||||
| Asset impairment and abandonments | 1,082 | 2,401 | 5,352 | 12,195 | ||||||||||||
| Transaction and financing expenses | 18,039 | 1,179 | 19,391 | 3,689 | ||||||||||||
| Severance and restructuring costs | 1,148 | (10 | ) | 1,148 | 208 | |||||||||||
| Adjusted EBITDA* | $ | (9,097 | ) | $ | (12,935 | ) | $ | (45,366 | ) | $ | (44,806 | ) | ||||
| Adjusted EBITDA as a percent of revenues | (44.2)% | (59.3)% | (55.3)% | (49.5)% | ||||||||||||
| *Please note this reconciliation does not include HOLO Portal capitalized costs of | ||||||||||||||||
| #See explanations in Non-GAAP Financial Measures above. | ||||||||||||||||
FAQ
What were Surgalign's financial results for Q4 2022?
How did Surgalign's gross margin change in Q4 2022?
What strategic actions did Surgalign take in 2023?
What is Surgalign's target for cash savings in 2023?
What was Surgalign's operating loss for Q4 2022?
